Holen Sie sich die Stockscreener-App
0.6159
2.58%
-0.0163
Handel nachbörslich:
.56
-0.0559
-9.08%
Schlusskurs vom Vortag:
$0.6322
Offen:
$0.63
24-Stunden-Volumen:
3.21M
Relative Volume:
0.26
Marktkapitalisierung:
$22.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-0.8359
EPS:
-0.7368
Netto-Cashflow:
-
1W Leistung:
-38.29%
1M Leistung:
+98.68%
6M Leistung:
-31.10%
1J Leistung:
-65.40%
1-Tages-Spanne:
$0.57
$0.64
1-Wochen-Bereich:
$0.47
$0.955
52-Wochen-Spanne:
$0.2027
$3.89
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Firmenname
Calidi Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 794-9600
Adresse
4475 Executive Drive, Suite 200, San Diego
Vergleichen Sie CLDI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.6159 | 34.45M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-09 | Eingeleitet | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
What makes Calidi Biotherapeutics Inc. stock price move sharplyFree Professional Portfolio Management - Newser
Why Calidi Biotherapeutics Inc. stock attracts strong analyst attentionFree Best Performing Stock Suggestions - Newser
How Calidi Biotherapeutics Inc. stock performs during market volatilityMarket Beating Strategy - Newser
Calidi Biotherapeutics Inc Inc. (CLDI) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Calidi Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks
Calidi Biotherapeutics Plummets 27%—Can Biotech Breakthroughs Stem the Slide? - AInvest
Top Penny Stocks To Add to Your Watchlist – July 9th - Defense World
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Calidi Biotherapeutics: Redefining Cancer Treatment with Breakthrough Virotherapy - AInvest
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment - The Manila Times
Breakthrough Cancer Treatment: Calidi's New Genetic Platform Targets Both Primary and Metastatic Tumors - Stock Titan
Calidi Biotherapeutics Cashes In On Warrant Agreement - Finimize
Calidi Biotherapeutics secures $4.6 million through warrant exercise - Investing.com Australia
Calidi Biotherapeutics secures $4.6 million through warrant exercise By Investing.com - Investing.com Nigeria
Calidi Biotherapeutics to Raise $4.6 Million Through Warrant Exercise Agreement - MarketScreener
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers - The Malaysian Reserve
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds - The Manila Times
Clinical-Stage Biotech Calidi Raises $4.6M in Fresh Capital: Accelerates Targeted Therapy Programs - Stock Titan
Crude Oil Moves Higher; RxSight Shares Plunge - Benzinga
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga
Calidi Biotherapeutics Stock Soars 174.93% on Precision Medicine Hype - AInvest
Calidi Biotherapeutics Soars 119.7% on Cancer Trial News - AInvest
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On - Benzinga
Revolutionary Cancer Treatment: How Engineered Viruses Could Transform Genetic Medicine Delivery - Stock Titan
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs – Company AnnouncementFT.com - Financial Times
Calidi Biotherapeutics (CLDI): A Breakthrough in Systemic Virotherapy and the $564B Oncology Opportunity - AInvest
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of… - Informazione.it
Calidi Biotherapeutics (NYSE:CLDI) Shares Up 5.6% – Still a Buy? - Defense World
CLDI SEC FilingsCalidi Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Calidi Biotherapeutics Granted Patent for Cell-Based Oncolytic Virus Immunotherapy for Cancer Treatment - ACCESS Newswire
Certain Warrants of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Calidi Biotherapeutics Announces Shareholder Letter from CEO - The Manila Times
Millennium Management LLC Increases Stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma, PhD, as CEO to Lead Next Growth Phase - citybuzz -
Jane Street Group LLC Takes Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025 - citybuzz -
Calidi Biotherapeutics Presents systemic oncolytic platform - GlobeNewswire
Calidi Biotherapeutics (CLDI) Showcases Innovative CLD-401 Thera - GuruFocus
Revolutionary Cancer Treatment Breakthrough: Calidi's New Systemic Delivery Platform Wows ASCO Conference - Stock Titan
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting - The Manila Times
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Shares Down 5.3% – Time to Sell? - Defense World
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results And Recent Operational Highlights - marketscreener.com
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewswire
Calidi Biotherapeutics Secures FDA Green Light for Cancer Trial as New CEO Reveals Q1 Financials - Stock Titan
Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World
Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
CLDICalidi Biotherapeutics Inc Latest Stock News & Market Updates - Stock Titan
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World
Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.37%
Kapitalisierung:
|
Volumen (24h):